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Abstract
Background: Primitive sarcoma of the breast is a rare and challenging disease at high risk of recurrence and with
poor prognosis. There are controversies in the diagnosis and management of such solid tumor due to its rarity and
heterogeneity. This sarcoma is poorly responsive to both chemotherapy and radiotherapy, thus, surgery is the first
and most important therapeutic approach. However, given the rarity of this type tumor it has not be possible to
standardize unique guidelines for the proper surgical strategy to adopt. Here, we performed a retrospective study
of new 10 cases of primitive sarcoma of the breast that underwent either mastectomy or a more conservative
quadrantectomy, in the attempt to better standardize correct surgical indications.
Methods: Ten new cases of primitive sarcoma of the breast were registered between 2002 and 2012 and
constituted the study group. They underwent either mastectomy or quadrantectomy and the clinical, prognostic
and survival characteristics after surgery were analysed.
Results: Within the group of patients treated with mastectomy, two had metastasis and died because of that.
Among the five patients treated with quadrantectomy four are alive and free of disease after 3 to 5 years follow-up,
while the patient with sarcoma arising in pregnancy, although is still alive, developed lung metastases four years
after surgery.
Conclusions: The first and most important therapeutic approach to primary sarcomas of the breast is surgical
which has the purpose to achieve radical tumor excision to prevent local recurrence and skip metastases. However,
given the rarity of the condition and the consequent small number of cases in this, like in similar studies, it is not
possible to draw any definitive conclusions and further studies with larger numbers are necessary. However it
would appear that performing a larger procedure such as mastectomy rather than performing a more limited one
such as a quadrantectomy, has no advantage in terms of overall prognosis.
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Introduction
Primary breast sarcoma (PBS) is a rare malignancy that
originates from the mesenchymal tissue of the mammary
gland. The variety of cells present in this tissue, such as
fat cells, muscle cells, or endothelial cells, accounts for
the heterogeneity of the histological types encountered:
liposarcomas, angiosarcomas, and leiomyosarcomas.
PBS represents <1 % of all primary breast malignancies
and <5 % of all sarcomas [1–4]. PBS is a typically female
disease that can rarely occur in male patients. Its natural
history does not significantly differ from that of sarcomas
of other anatomical sites, except for the angiosarcoma
which has a more severe prognosis [5]. PBS can some-
times be diagnosed too late even in patients undergoing
screening visits, due to the initial characteristics of this
tumor that can mimic benign lesions, such as fibroaden-
oma or phyllodes tumor [6–8] and a correct diagnosis is
important for planning efficacious surgery treatments.
Five years overall survival (OS) does not exceed 55 %
and it is influenced by several factors such as tumor
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localization and dimension, histological features and
resection margin status [9–14].
Due to the rarity of the PBS, it appears difficult to de-
velop univocal guidelines both for the surgical treatment
and for any subsequent specific therapy for the breast
[9]. Thus, most of the published studies are case reports
or studies on small groups of patients. PBS, like all sar-
comas, is poorly responsive both to chemotherapy and
radiotherapy, although the role of adjuvant radiation or
chemotherapy is still unclear in light of the limited size
of study reports [7, 15, 16]. The first and most important
treatment for PBS is surgery which has the purpose to
obtain radical excision of the tumor, with negative mar-
gins (R0) and to avoid local tumor recurrence linked to
the presence of possible skip metastases [17, 18]. A cor-
rect surgical approach is important in many tumors, as
also shown by our studies [19]. In order to standardize
the surgical approach for limb sarcomas, in 1983
Enneking proposed different types of surgery: 1) intra-
lesional or contaminated surgery, when the tumor is
sectioned or broken during the surgical excision; 2)
marginal surgery when the tumor is completely re-
moved following the margin of psudocapsule, although
skip metastases can occur; 3) wide surgery, when the
tumor is completely removed along with a clear layer of
normal peritumoral tissue; and 4) compartmental surgery,
when the anatomical compartment site of the tumor is
completely removed [20, 21]. Compartmental treatment
or wide excision are usually considered sufficiently cura-
tive in sarcoma management, with resection margins of at
least 1–2 cm of normal peritumoral tissue to avoid skip
metastasis [21–24].
In the attempt to better standardize correct surgical
indications for PBS, we performed a retrospective review
of 10 new cases of PBS registered from 2002 to 2012
that underwent either mastectomy or a more conserva-
tive quadrantectomy in our Surgical Departments, and




Patients with PBS were treated in the Department of
Surgical Sciences, Sapienza University of Rome and in
the Department of Gynecology, “Fabia Mater” Hospital
in Rome, Italy, between 2002 and 2012. A total of 10
cases, 9 female and 1 male, were reported in the study.
Clinical characteristics, including treatment strategies
(i.e., type of surgery, radiotherapy and chemotherapy),
histological type, and tumor size were retrospectively an-
alyzed from the medical records. The follow-up informa-
tion was acquired from the database, the medical records
and contact with the patients or their families. Patients
were classified into two groups (five patients/each) based
on the type of the performed surgery: in the first group
the patients (including the only male) were treated with
mastectomy; in the second group the patients were treated
with the more conservative quadrantectomy (Table 1).
All participants provided written informed consent be-
fore participating in this study.
The study was carried out according to the Helsinki
Declaration.
Results
Clinical and surgical data
Overall, 10 patients constituted the study group. They
were 9 female and 1 male with median age at diagnosis of
primary carcinoma of 52.8 years. One patients was <40
years, 5 patients were <60 years, and 4 patients were >60
years at diagnosis (Table 1). The histological analyses
showed different istotypes within the two surgical treated
groups (Table 1). Tumours were mainly localized in the
right chest (7/10) and the size was described by the path-
ologist for all patients with a median of about 101.6mm
Table 1 Patients, tumor type, surgical treatment and adjuvant therapies
No. Sex Age years Tumor type Surgical treatment Adjuvant treatment
1 F 46 Stromal sarcoma Mastectomy chemo + radio
2 F 33 Angiosarcoma Mastectomy chemo + radio
3 F 41 Phylloides tumor Mastectomy chemo + radio
4 F 73 Pleomorphic sarcoma Mastectomy chemo + radio
5 M 69 Liposarcoma Mastectomy chemo + radio
6 F 45 Phylloides tumor borderline Quadrantectomy N/A
7 F 51 Phylloides tumor
low grade
Quadrantectomy N/A
8 F 63 Chondrosarcoma Quadrantectomy chemo + radio
9 F 64 Epithelial/mesenchymal
tumor
Quadrantectomy N/A
10 F 43 Sarcoma in phylloides
tumor
Quadrantectomy N/A
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(range 15 to 160 mm); a mitosis count was performed for
all patients showing 50% up to ten mitoses per field; six
out of 10 patients presented severe cellular atypia
(Table 2).
In the first group, treated with mastectomy, the five
patients were affected by, respectively, stromal sarcoma,
angiosarcoma, phyllodes tumor with a high degree of
malignancy, pleomorphic sarcoma, and liposarcoma
(Table 1). The first three patients underwent total mast-
ectomy after a previous not adequate lumpectomy in a
different Hospital that left residual tumor on the mar-
gins of resection, as evaluated by histologic examination.
The patient with phyllodes tumor with a high degree of
malignancy underwent mastectomy because the size of
tumor (about 150 mm of diameter) while the patient
with liposarcoma (the only male) could not undergo
conservative surgery due to the lack of available margins.
The patients undergoing mastectomy, after a not ad-
equate surgery, were subsequently treated with radio-
therapy (50 Gy preoperative - 60 Gy postoperative in 30
fractions) and adjuvant chemotherapy (Epirubicin 60
mg/m2 day 1, 2; Ifosfamide 3g/m2 day 1, 2, 3; Mesna
3g/day 1, 2, 3, for 5 cycles).
In the second group, treated with more conservative
quadrantectomy, the patients were affected by, respect-
ively, borderline phyllodes tumor, chondrosarcoma,
mixed epithelial/mesenchymal tumor, phyllodes tumor
with low grade of malignancy, and sarcoma (Table 1).
This last one was diagnosed in a pregnant patient and
presented an unusual concentric lesion with sarcomatous
tissue in the center, phyllodes tumor in the intermediate
layer and tissue with histological features of fibroadenoma
outside (Fig. 1). Among the patients undergoing quadran-
tectomy only the condrosarcoma patient was treated with
radiotherapy (60 Gy in 30 fractions) and adjuvant chemo-
therapy (Epirubicin 60 mg/m2 day 1, 2; Ifosfamide 3g/
m2 day 1, 2, 3; Mesna 3g/day 1, 2, 3, for 3–5 cycles).
Survival data
To try to standardize general surgical indications for
PBS we next analysed overall survival (OS) as the time
from the surgery until death by any cause (Table 3).
Among the five patients treated with mastectomy, the
one with pleomorphic sarcoma died 1 year after surgery
because the appearance of distant metastases while the
patient with stromal sarcoma died 6 years after surgery,
despite the more demolitive surgery performed. The
other three patients treated with total mastectomy after
lumpectomy underwent local recurrence of the disease
and needed a new surgery, however, after 4 to 5 years
follow-up they are free of disease.
Among the five patients treated with the more conser-
vative quadrantectomy four are alive and free of disease
after 3 to 5 years follow-up, including the borderline phyl-
lodes tumor patient, despite the large size of the tumor
compared to the breast (Fig. 2), the chondrosarcoma
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Fig. 1 Photomicrograph showing breast sarcoma with unusual
concentric lesion with sarcomatous tissue in the center, phyllodes
tumor in the intermediate layer and tissue with histological features
of fibroadenoma outside (magnification, x40)
Pasta et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:72 Page 3 of 6
patient, the mixed epithelial/mesenchymal metaplastic
carcinoma patient and the phyllodes tumor with low grade
malignancy patient. The mixed epithelial/mesenchymal
metaplastic carcinoma patient, due to dual nature of the
tumor, underwent outer quadrantectomy of the right
breast with equatorial enlargement of the distal and prox-
imal margins and removal of the sentinel lymph node with
mixed reactive hyperplastic chronic lymphadenitis. Differ-
ent was the course of the sarcoma arising in pregnancy,
whereas excision of the lesion (with local anesthesia for
gestational status of the patient) was followed by a subse-
quent further enlargement of resection margins, consider-
ing the final histological examination. Four years after
surgery the patient developed lung metastases and is still
alive underlying the importance of a correct surgical ap-
proach since the beginning (in this case, surgery was influ-
enced by the pregnancy status of the patient).
Discussion
Sarcoma of the breast is a very rare disease which repre-
sents <1% of breast cancers and <5% of all location sar-
comas [15, 25]. For this reason, it is difficult to identify a
specific treatment for these patients. There is widespread
acceptance that surgical resection should be the first
modality of treatment for breast sarcoma. However, it is
still unclear which would be the surgical treatment with
the best outcome for the patients [17, 18].
The purpose of surgery is excellent local control and
for many years, mastectomy was regarded as the gold
standard. The choice of a more or less demolitive surgi-
cal intervention (respectively, mastectomy and quadran-
tectomy) is based on the possibility to obtain adequate
margins of healthy peritumoral tissue which would en-
sure both the complete removal of the tumor and the
excision of possible skip metastases, that unlike what
happens in other tumors, including melanoma, are not
detectable by instrumental examinations [22–26]. To
reach this goal, it is particularly important to evaluate
the tumor/breast size ratio before surgery in order to
properly perform a correct planning of the surgical strat-
egy which could include even conservative surgery with-
out compromising the prognosis [27]. Thus, we showed
here that, despite the large size of the tumor compared
to the breast (Fig. 2), the borderline phyllodes tumor pa-
tient was treated with the more conservative quadran-
tectomy that allowed to keep the patient still alive and
free of disease after 5 years follow-up.
About the two patients undergoing mastectomy and
that subsequently died of recurrent disease, it should be
highlighted that the first case was a reoperation after in-
adequate excision previously performed elsewhere, while
in the second case the diameter of the tumor (160 mm)
and the tumor/breast size ratio did not allow another
type of surgical approach. Among the patients treated
Table 3 Patients, tumor type, and overall survival (OS)




1 Stromal sarcoma Mastectomy 6 years deceased
2 Angiosarcoma Mastectomy 4 years yes
3 Phylloides tumor Mastectomy 5 years yes
4 Pleomorphic sarcoma Mastectomy 1 years deceased
5 Liposarcoma Mastectomy 4 years yes
6 Phylloides tumor
borderline
Quadrantectomy 5 years yes
7 Phylloides tumor low
grade
Quadrantectomy 5 years yes
8 Chondrosarcoma Quadrantectomy 5 years yes
9 Epithelial/mesenchymal
tumor
Quadrantectomy 3 years yes
10 Sarcoma in phylloides
tumor
Quadrantectomy 5 years metastases
Fig. 2 (a), (b) Macroscopic aspects of borderline phyllodes tumor
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with quadrantectomy, it was particularly interesting the
case of the pregnant woman with “concentric” lesion
(center sarcoma, intermediate layer phyllodes, outside
fibroadenoma). This particular situation occurred in
pregnancy did suggest the possible malignant evolution
(from center to the periphery) of mesenchymal lesions
originally benign, even if the observation of a single case
allows us to only assume this type of evolution. Some
studies show significantly increased OS after total mast-
ectomy as compared with conservative surgery in PBS
patients [8]. In contrast, other studies have demonstrated
no significant advantage to mastectomy in comparison
with wide local excision [1, 16, 28–30]. This is similar to
our observation on the treatment of PBS patients.
Furthermore, local recurrence rate varies according to
the location, the histological type and technical possibil-
ities to perform a wide or compartmental excision [31].
Surgery is the first and most effective treatment for these
tumors and indeed, with resection margins of less than
1 cm, the local recurrence rate is around 13%, while with
resection margins larger than 1 cm local recurrence rate is
around 0% [11, 32], since with wide resection margins the
so-called skip metastasis are removed en bloc with the
tumor. Therefore, surgeons must pay particular attention
to the characteristics of the resection margins [7, 33, 34].
Importantly, only for angiosarcomas resection margins
must be at least 3 cm of healthy peritumoral tissue, while
for all other sarcomas of the breast a margin of 1 cm is
considered sufficiently curative [15].
Mastectomy for mesenchymal neoplasms should not nor-
mally be performed with axillary lymphadenectomy, since
these tumors mainly spread by blood vessels; the axillary
lymphadenectomy may expose the patient to increased
morbidity with no significant increase of disease-free sur-
vival and overall survival rate. Conversely for mixed tumors,
lymphadenopathy or for the tumors along the axillary fold,
sentinel lymph node biopsy can be considered [27].
Thanks to core-byopsy examination, we were actually
able to identify both the degree and the histological type
of the tumors, and we could better plan the preoperative
surgical approach to sarcomas [31]. Furthermore, the
new concepts about the embryonic development of the
breast have redefined the idea of surgical anatomical
compartment [35]. Indeed, thanks to recent studies on
embryonic development of the mammary gland, a separ-
ate origin of the various glandular segments or lobules
has been hypothesized and, therefore, the removal of an
anatomical segment or quadrant can be considered as
the resection of the corresponding anatomical compart-
ment (compartmental surgery) [35].
After surgery, depending on the risk of relapse (related
to the diameter, location and grade of the tumor) adjuvant
radiation therapy may be indicated, possibly associated
with chemotherapy. Radiotherapy (preoperative 50 Gy,
postoperative 60 Gy) is really important in the treatment
of sarcomas, since it allows, if used in combination with
surgery and also for conservative surgery, to achieve re-
sults comparable to those obtained with radical, demoli-
tive surgery. Chemotherapy (Epirubicin 60 mg/m2 day 1,
2; Ifosfamide 3 g/m2 day 1, 2, 3; Mesna 3 g/day 1, 2, 3, for
3–5 cycles) may represent advantage for patients with
high-risk lesions [24].
In summary, in literature, we did not find that mastec-
tomy has a better chance of long-term survival for sarco-
mas of the breast compared to wide excision or to
quadrantectomy, while the simple lumpectomy has a
more severe prognosis [27]. In our experience, the histo-
logical features and the correct first surgical approach
influenced the prognosis more than the size of the
tumor, and obviously, early diagnosis is fundamental, as
indeed for all cancers.
Conclusions
Sarcomas of the breast, like all sarcomas, are poorly re-
sponsive both to chemotherapy and radiotherapy and,
therefore, surgery has the most important role. Concern-
ing the prognosis, surgery has the purpose to obtain a
radical excision (R0 margins), avoiding local recurrence
linked to the presence of possible "skip metastases". As
highlighted in some of our cases, surgery is not effective
in preventing distant metastases if they were already
present at the time of the operation, even if not still
diagnosable. Wide demolitive surgery (based on old con-
cept of anatomical compartment) not always positively
influences the prognosis, and even our study shows that
the prognosis is mainly influenced by aggressiveness of
the tumor, evaluated with a preoperative biopsy, correct
first surgical approach and treatment, and early diagno-
sis. Furthermore, we do not have to underestimate func-
tional, aesthetic and psychological aspects that may
influence the quality of patients life after a more demoli-
tive surgery, sometimes without a real improvement of
disease-free period and overall survival.
Recent embryological studies confirm segmental/lobu-
lar origin of breast cancer. Thanks to these new infor-
mations we have now a different concept of anatomical
compartment for sarcomas of the breast and, when pos-
sible, we can choose to perform less demolitive opera-
tions (quadrantectomy) with the same results of a more
aggressive but not more useful surgery. The adjuvant
radiotherapy following conservative surgery is surely
useful in monitoring local recurrences, especially for lar-
ger and high grade tumors. The role of adjuvant chemo-
therapy is still controversial, and it may be indicated for
more severe prognosis cancers.
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